IT’S ALL ABOUT ACCESS: GOVERNMENT & PATIENT GROUPS TO DISCUSS AND COLLABORATE
Access. The single biggest problem preventing rare disease patients from getting
proper medical care in the Asia-Pacific region.
How can I, as a patient, get physical access to orphan drugs?
Join us and discuss challenges from the lack of harmony in policies and subsidies in countries across the region to import & trade differences, affordability issues and overall sustainability concerns.
Can orphan drugs leverage the ASEAN harmonization efforts?
How is it that some countries have a Rare Disease Act and others don’t?
Why do some reimburse and others don’t?
Can wholesale specialty pharmacies accessing orphan drugs for the entire region resolve issues around cost-efficiency and sustainability?
How can we articulate the value of orphan drugs for Asian patients in a different way to the HTAs that have been re-evaluated in Europe and the US?
We bring these issues to the
World Orphan Drug Congress Asia in 2017
Join governments, regulators, patient groups and orphan drug manufacturers in Singapore on 21 March 2017 so we can ensure rare disease patients get proper medical care.